Gottlieb J A, Benjamin R S, Baker L H, O'Bryan R M, Sinkovics J G, Hoogstraten B, Quagliana J M, Rivkin S E, Bodey G P, Rodriguez V, Blumenschein G R, Saiki J H, Coltman C, Burgess M A, Sullivan P, Thigpen T, Bottomley R, Balcerzak S, Moon T E
Cancer Treat Rep. 1976 Feb;60(2):199-203.
DTIC was one of the first of several new agents evaluated by the Southwest Oncology Group (SWOG) and the M.D. Anderson Hospital and Tumor Institute (MDAH) in the therapy of adult patients with metastatic sarcomas. It yielded an overall response rate of 17%. This is similar to that seen in a review of 138 patients who represent the total number reported in either published or unpublished data. The subsequent addition of DTIC to adriamycin in several studies carried out at the MDAH and in the SWOG has increased the complete and partial remission rate over that seen with adriamycin alone, and more importantly has increased remission duration and survival. DTIC is currently used in combination with adriamycin in the first-line therapy of patients with metastatic sarcomas and should be considered for patients who have relapsed on primary therapy not including DTIC.
氮烯咪胺（DTIC）是西南肿瘤协作组（SWOG）和MD安德森医院肿瘤研究所（MDAH）评估的用于治疗成人转移性肉瘤患者的首批几种新药之一。其总体缓解率为17%。这与对138名患者的回顾结果相似，这些患者代表了已发表或未发表数据中报告的总数。随后在MDAH和SWOG进行的几项研究中，将氮烯咪胺与阿霉素联合使用，与单独使用阿霉素相比，完全缓解率和部分缓解率有所提高，更重要的是缓解持续时间和生存期有所延长。氮烯咪胺目前用于转移性肉瘤患者的一线治疗，与阿霉素联合使用，对于在不包括氮烯咪胺的初始治疗中复发的患者也应考虑使用。
